JP7836762B2 - ヘテロ環glp-1アゴニスト - Google Patents
ヘテロ環glp-1アゴニストInfo
- Publication number
- JP7836762B2 JP7836762B2 JP2022549132A JP2022549132A JP7836762B2 JP 7836762 B2 JP7836762 B2 JP 7836762B2 JP 2022549132 A JP2022549132 A JP 2022549132A JP 2022549132 A JP2022549132 A JP 2022549132A JP 7836762 B2 JP7836762 B2 JP 7836762B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- ring
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025281655A JP2026076168A (ja) | 2020-02-13 | 2025-12-25 | ヘテロ環glp-1アゴニスト |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020075105 | 2020-02-13 | ||
| CNPCT/CN2020/075105 | 2020-02-13 | ||
| CN2020075103 | 2020-02-13 | ||
| CNPCT/CN2020/075103 | 2020-02-13 | ||
| PCT/CN2021/076260 WO2021160127A1 (en) | 2020-02-13 | 2021-02-09 | Heterocyclic glp-1 agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025281655A Division JP2026076168A (ja) | 2020-02-13 | 2025-12-25 | ヘテロ環glp-1アゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023515404A JP2023515404A (ja) | 2023-04-13 |
| JP2023515404A5 JP2023515404A5 (cg-RX-API-DMAC10.html) | 2024-02-20 |
| JP7836762B2 true JP7836762B2 (ja) | 2026-03-27 |
Family
ID=77291666
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549132A Active JP7836762B2 (ja) | 2020-02-13 | 2021-02-09 | ヘテロ環glp-1アゴニスト |
| JP2025281655A Pending JP2026076168A (ja) | 2020-02-13 | 2025-12-25 | ヘテロ環glp-1アゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025281655A Pending JP2026076168A (ja) | 2020-02-13 | 2025-12-25 | ヘテロ環glp-1アゴニスト |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230165846A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4103563A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7836762B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN115697999A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021160127A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191432A1 (ru) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| AU2020256647B2 (en) * | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| EP4069686B1 (en) * | 2019-12-02 | 2025-01-22 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| MX2022011349A (es) * | 2020-03-18 | 2022-11-10 | Lg Chemical Ltd | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
| WO2022052958A1 (en) | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022111624A1 (zh) * | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| EP4317145A4 (en) | 2021-03-24 | 2025-03-12 | Shionogi & Co., Ltd | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| US20240300928A1 (en) * | 2021-04-08 | 2024-09-12 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| LT4271672T (lt) | 2021-04-21 | 2026-03-10 | Gilead Sciences, Inc. | Karboksibenzimidazolo junginiai, moduliuojantys glp-1r |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CN117098758A (zh) | 2021-06-24 | 2023-11-21 | 杭州中美华东制药有限公司 | Glp-1受体激动剂及其组合物和用途 |
| CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
| KR20240056719A (ko) | 2021-09-08 | 2024-04-30 | 시오노기 앤드 컴파니, 리미티드 | 항비만 작용이 관여하는 질환의 예방 및 치료용 의약 |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| US20250236627A1 (en) | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| CN116574092B (zh) * | 2022-05-20 | 2024-08-20 | 成都地奥九泓制药厂 | 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用 |
| CN119923395A (zh) * | 2022-07-27 | 2025-05-02 | 卡莫特医疗有限公司 | N-杂环gpcr受体激动剂、包含其的药物组合物和其使用方法 |
| CN119907794A (zh) | 2022-09-22 | 2025-04-29 | 盐野义制药株式会社 | 具有glp-1受体激动剂作用的稠环化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CR20250178A (es) | 2022-11-16 | 2025-06-06 | Lilly Co Eli | Agonistas del receptor del péptido-1 similar al glucagón |
| JP2026501161A (ja) * | 2022-12-13 | 2026-01-14 | 杭州中美華東製薬有限公司 | Glp-1受容体作動薬の新規結晶形、その製造方法、その医薬組成物およびその使用 |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| AU2024380885A1 (en) * | 2023-11-13 | 2026-05-14 | Aspen Neuroscience, Inc. | Methods of predicting characteristics of differentiated neuronal cells |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| KR20260038229A (ko) | 2024-09-11 | 2026-03-18 | 한미약품 주식회사 | Glp-1 수용체 작용제 및 이의 용도 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020511411A (ja) | 2016-12-16 | 2020-04-16 | ファイザー・インク | Glp−1受容体アゴニストおよびその使用 |
| JP2021528394A (ja) | 2018-06-15 | 2021-10-21 | ファイザー・インク | Glp−1受容体アゴニストおよびその使用 |
| JP2022508203A (ja) | 2018-11-22 | 2022-01-19 | キル・レガー・セラピューティクス・インコーポレーテッド | Glp-1rアゴニスト及びその使用 |
| JP2022527607A (ja) | 2019-04-12 | 2022-06-02 | キル・レガー・セラピューティクス・インコーポレーテッド | Glp-1rアゴニスト及びその使用 |
| JP2022540044A (ja) | 2019-06-28 | 2022-09-14 | イーライ リリー アンド カンパニー | グルカゴン様ペプチド1受容体アゴニスト |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021018023A1 (zh) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| CR20220178A (es) * | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| EP4069686B1 (en) * | 2019-12-02 | 2025-01-22 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
-
2021
- 2021-02-09 CN CN202180026644.6A patent/CN115697999A/zh active Pending
- 2021-02-09 JP JP2022549132A patent/JP7836762B2/ja active Active
- 2021-02-09 EP EP21753402.3A patent/EP4103563A4/en active Pending
- 2021-02-09 WO PCT/CN2021/076260 patent/WO2021160127A1/en not_active Ceased
- 2021-02-09 US US17/799,609 patent/US20230165846A1/en active Pending
-
2025
- 2025-12-25 JP JP2025281655A patent/JP2026076168A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020511411A (ja) | 2016-12-16 | 2020-04-16 | ファイザー・インク | Glp−1受容体アゴニストおよびその使用 |
| JP2021528394A (ja) | 2018-06-15 | 2021-10-21 | ファイザー・インク | Glp−1受容体アゴニストおよびその使用 |
| JP2022508203A (ja) | 2018-11-22 | 2022-01-19 | キル・レガー・セラピューティクス・インコーポレーテッド | Glp-1rアゴニスト及びその使用 |
| JP2022527607A (ja) | 2019-04-12 | 2022-06-02 | キル・レガー・セラピューティクス・インコーポレーテッド | Glp-1rアゴニスト及びその使用 |
| JP2022540044A (ja) | 2019-06-28 | 2022-09-14 | イーライ リリー アンド カンパニー | グルカゴン様ペプチド1受容体アゴニスト |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023515404A (ja) | 2023-04-13 |
| EP4103563A4 (en) | 2024-03-06 |
| US20230165846A1 (en) | 2023-06-01 |
| WO2021160127A1 (en) | 2021-08-19 |
| EP4103563A1 (en) | 2022-12-21 |
| JP2026076168A (ja) | 2026-05-11 |
| CN115697999A (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026076168A (ja) | ヘテロ環glp-1アゴニスト | |
| US11926643B2 (en) | Heterocyclic GLP-1 agonists | |
| US12552791B2 (en) | Heterocyclic GLP-1 agonists | |
| US12528781B2 (en) | Heterocyclic GLP-1 agonists | |
| US20240366639A1 (en) | Heterocyclic glp-1 agonists | |
| EP4490155A1 (en) | Heterocyclic glp-1 agonists | |
| WO2023151575A1 (en) | Heterocyclic glp-1 agonists | |
| HK40118610A (en) | Heterocyclic glp-1 agonists | |
| HK40122544A (en) | Heterocyclic glp-1 agonists | |
| HK40083559A (en) | Heterocyclic glp-1 agonists | |
| HK40083559B (en) | Heterocyclic glp-1 agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240208 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240208 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250509 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260109 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260206 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260217 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260316 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7836762 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |